Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of the American College of Cardiology (JACC)
First randomized evidence supporting feasibility of maintaining cardiac stability with carvedilol alone after systematic withdrawal of other heart failure medications in selected patients.
Cardiology June 3rd 2025
Registry data shows that comorbidities not captured in traditional surgical risk scores, particularly atrial fibrillation and poor baseline functional status, significantly impact post-TAVR outcomes in low-risk patients.
Cardiology May 6th 2025
Cath Lab Digest
DETECT AS trial showed electronic notifications increased AVR rates by 11% overall and 14% in symptomatic patients, while EARLY TAVR analyses confirmed superior outcomes with timely intervention versus surveillance, with biomarkers failing to predict optimal treatment timing.
Epoch Health
The article presents evidence suggesting cardiovascular risk may correlate more strongly with inflammatory processes than cholesterol levels, recommending CRP monitoring alongside comprehensive biomarker assessment and lifestyle modifications targeting inflammation reduction through carbohydrate restriction.
MedCentral
The study identifies three scenarios where CAC testing provides limited value: “too early” (younger patients without risk factors), “too late” (elderly patients or those already on statins), and “too often” (repeated imaging after statin initiation).
FRESH-UP found no benefit in health status, hospitalizations, or mortality when restricting fluids to 1,500 mL daily in stable heart failure patients, while significantly increasing thirst distress.